Stockholders Approve Significant Increase in Authorized Shares, Enabling Future Dilution
summarizeSummary
PURE BIOSCIENCE, INC. stockholders approved an amendment to increase authorized common stock by 50 million shares, from 200 million to 250 million, providing substantial headroom for future capital raises.
check_boxKey Events
-
Authorized Shares Increased
Stockholders approved an amendment to the Certificate of Incorporation, increasing the authorized number of common stock shares from 200,000,000 to 250,000,000 shares. This authorizes the company to issue up to 50,000,000 additional shares.
-
Significant Potential Dilution
If all authorized shares were issued, the potential dilution would be approximately 123% of the current 111,886,485 outstanding shares.
-
Director Elections
Seven directors (Tom Y. Lee, Ivan Chen, Tom Myers, David M. Rendall, Robert Bartlett, Bernard Blotner, and Darin Zehr) were re-elected to the Board of Directors.
-
Auditor Ratification
Weinberg & Company, P.A. was ratified as the independent registered public accounting firm for the fiscal year ending July 31, 2026.
auto_awesomeAnalysis
PURE BIOSCIENCE, INC. stockholders approved an amendment to increase the authorized common stock by 50 million shares, from 200 million to 250 million. This authorization provides the company with substantial flexibility to issue new shares in the future. If all authorized shares were issued, the potential dilution would be approximately 123% of the current outstanding shares. While this filing only grants permission and no shares have been sold, it signals the company's ability to raise significant capital through potentially dilutive offerings, which could materially impact existing shareholder value for this micro-cap company. Investors should monitor for subsequent filings detailing actual share issuances.
At the time of this filing, PURE was trading at $0.06 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $0.04 to $0.21. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.